Phase I-II, Open Label, Uncontrolled, Dose Escalation Study of the Safety, Tolerability and Biologic Activity of the INFRADURE Biopump Secreting Sustained Interferon Alpha-2b (IFNα), in Combination With Oral Ribavirin for Genotype 3 Newly Diagnosed Hepatitis C Patients
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2015
At a glance
- Drugs AAV-IFNA2B gene therapy Medgenics (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Aevi Genomic Medicine
- 16 Apr 2014 Status changed to discontinued as reported by ClinicalTrials.gov record.
- 10 Sep 2012 Official title amended as reported by ClinicalTrials.gov.
- 10 Sep 2012 Planned End Date changed from 1 Nov 2012 to 1 Nov 2013 as reported by ClinicalTrials.gov.